This website is for Private Investors* only
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
- Obtains access to the information in a personal capacity;
- Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
- Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
- Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
- Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
- Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Tell us more
You are seeing these quotes based on previous browsing related to sectors such as
AstraZeneca (AZN)
8,785.00p
13:50 23/09/20
- 2.39% 205.00p
- Today's Low & High
- 8,678.00 / 8,825.00
- Open / Previous Close
- 8,743.00 / 8,580.00
- 52-week range
- 22.52% 1,615.00p
- Volume
- 1,007,782
- Market Cap(billion)
- £115.28b
8,807.00p
REAL TIME
- 15:08 23/09/20
- 1.98%
- 171.00p
Advertising
KEY FINANCIALS
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.6% | 2.5% |
| Div Cover | 0.4 | 1.4 |
| Op Mrgn | 12.0% | 24.9% |
| ROCE | 76.9% |
| Latest | Forecast | |
|---|---|---|
| P/E | 106.0 | 27.9 |
| PEG | -2.7 | 0.1 |
| Price / Revenue | 5.9 | 5.5 |
| Price / Book value | 9.8 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 10.4% | -2.2% |
| PBT | -22.3% | n/a |
| EPS | -39.4% | -6.3% |
| DPS | 0.0% | -3.2% |
KEY FUNDAMENTALS
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | 24,708.00 | 3,069.00 | $4.26 | 16.0 | -34.2 | 0% | $2.80 | 4.1% |
| 2016-12-31 | 23,002.00 | 3,552.00 | $4.31 | 12.7 | 10.8 | 1% | $2.80 | 5.1% |
| 2017-12-31 | 22,465.00 | 2,227.00 | $4.28 | 16.2 | -23.2 | -1% | $2.80 | 4.0% |
| 2018-12-31 | 22,090.00 | 1,993.00 | $1.70 | 44.0 | -0.7 | -60% | $2.80 | 3.7% |
| 2019-12-31 | 24,384.00 | 1,548.00 | $1.03 | 97.9 | -2.5 | -39% | $2.80 | 2.8% |
FORECAST
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | 20,511.78 | 5,115.85 | 303.39p | 27.9 | 0.1 | 281% | 216.50p | 2.5% |
| 2021-12-31 | 23,038.88 | 6,409.65 | 385.94p | 22.4 | 0.8 | 27% | 219.02p | 2.5% |
Latest Webfg News
| AstraZeneca 'under fire' for vaccine safety, NYT says Sharecast News | 21 Sep |
|---|---|
| AstraZeneca's Tagriso trial shows 'meaningful improvement', Lynparza recommended for EU marketing Sharecast News | 21 Sep |
| Illness in phase three trial not linked to Covid-19 vaccine, Oxford says Sharecast News | 17 Sep |
Regulatory News
| Lynparza EU recommendation in prostate cancer | 21-Sep-20 07:12 |
|---|---|
| Lynparza EU recommendation in ovarian cancer | 21-Sep-20 07:05 |
| Tagrisso reduced early lung cancer brain recurrenc | 21-Sep-20 07:04 |
| AstraZeneca to list all US securities on Nasdaq | 10-Sep-20 07:12 |
| Fasenra PhIII OSTRO trial met co-primary endpoints | 10-Sep-20 07:06 |